Use of migalastat for treating fabry disease in pregnant patients
Migalastat treatment effectively stabilizes the α-Gal A enzyme in pregnant patients with Fabry disease, allowing for the birth of healthy children, addressing the limitations of existing therapies and ensuring safety during pregnancy.
Patent Information
- Application Number
- JP2024112288
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-02-06
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for Fabry disease, such as enzyme replacement therapy and pharmacological chaperones, have limitations, particularly during pregnancy, and there is a need for effective therapies for pregnant patients with Fabry disease.
Administering migalastat or its salt, such as migalastat hydrochloride, in a therapeutically effective dose of about 100 mg to 150 mg free base equivalent (FBE) every other day for at least two weeks to pregnant patients, potentially extending up to 16 weeks, to stabilize and enhance the activity of the α-Gal A enzyme, thereby reducing misfolded protein accumulation and associated symptoms.
Migalastat treatment during pregnancy results in the birth of children without defects, indicating its safety and efficacy in treating Fabry disease without adverse effects on the mother or offspring, with potential long-term benefits for both.
Smart Images

Figure 2024161361000001_ABST
Abstract
Description
[Technical field]
[0001] Principles and embodiments of the present invention relate generally to the use of pharmacological chaperones for the treatment of Fabry disease, particularly in pregnant or childbearing patients.
[0002] Array list reference The Sequence Listing text file submitted herewith, identified as "00790785.TXT" (22Kb, created February 6, 2019), is hereby incorporated by reference. [Background technology]
[0003] Many human diseases result from mutations that can cause changes in the amino acid sequence of a protein, reducing its stability and disrupting its proper folding. Proteins are generally folded in a specific area of the cell known as the endoplasmic reticulum or ER. Cells have quality control mechanisms that ensure that proteins fold into their correct three-dimensional shape and then allow them to move from the ER to their appropriate destination within the cell, a process commonly referred to as protein trafficking. Misfolded proteins are often initially retained in the ER before being excreted by quality control mechanisms. In certain cases, misfolded proteins can accumulate in the ER before being excreted. Retention of misfolded proteins in the ER can disrupt their proper trafficking, resulting in reduced biological activity and impaired cell function, which can ultimately lead to disease. In addition, accumulation of misfolded proteins in the ER can bring various types of stress to the cell and contribute to cell dysfunction and disease.
[0004] Lysosomal storage diseases (LSDs) are characterized by lysosomal enzyme deficiencies due to mutations in the genes encoding these enzymes, which result in the pathological accumulation of substrates for those enzymes, including lipids, carbohydrates and polysaccharides.
[0005] Fabry disease is a progressive X-linked congenital abnormality of glycosphingolipid metabolism caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A) as a result of mutations in the α-Gal A gene (GLA). Despite being an X-linked disorder, females can develop clinical symptoms to varying degrees. Fabry is a rare disorder estimated to occur in 1 in 40,000 to 1 in 117,000 males in the general population. In addition, there are late-onset phenotypic variants of Fabry disease that may be underdiagnosed because they do not present with the classical signs and symptoms. This, along with newborn screening for Fabry disease, suggests that the actual incidence of Fabry disease may be higher than current estimates.
[0006] Untreated, vascular disease affects the kidneys, heart, and / or central nervous system, reducing life expectancy and usually resulting in death in the third or fourth decade of life. Enzyme deficiency leads to intracellular accumulation of the substrate globotriaosylceramide (GL-3) in vascular endothelial and visceral tissues throughout the body. Progressive deterioration of renal function and azotemia due to glycosphingolipid deposition usually occurs during the second to fourth decades of life, but may occur as early as the first decade of life. Renal involvement is found in both hemizygous (males) and heterozygous (females) patients.
[0007] Cardiac disease develops in most men and many women as a result of Fabry disease. Early cardiac findings include left ventricular enlargement, valvular disorders, and conduction abnormalities. Mitral valve insufficiency is the most frequent valvular lesion, typically presenting in childhood or adolescence. Cerebrovascular symptoms arise primarily from multifocal small vessel disease and may include thrombosis, transient ischemic attacks, basilar artery ischemia and aneurysms, stroke, hemiplegia, hemisensory loss, aphasia, labyrinthine disorders, or cerebral hemorrhage. The average age at onset of cerebrovascular symptoms is 33.8 years. Personality changes and psychotic behavior may appear with increasing age.
[0008] Fabry disease usually presents with cutaneous symptoms, most commonly angiokeratomas (small papules that can be present anywhere on the body). Angiokeratomas appear as dark red or purple skin lesions ranging in size up to a few millimeters in diameter. Lesions usually appear during puberty or young adulthood and may increase with age. Other skin and soft tissue related symptoms include acroparesthesia, dyshidrosis (hyposhidrosis and hyperhidrosis) and lymphedema. The presence and extent of cutaneous vascular lesions may be related to the severity of the systemic disease.
[0009] In addition to skin symptoms, patients frequently experience neuropathy, such as burning pain in the extremities (acropesthesia, often in the hands and feet). Patients may also experience pain crises that begin with pain in the extremities and radiate inwards, lasting for several days. Neuropathic pain is pain resulting from damage to the somatosensory nervous system. Many types of sensory receptors are affected, including the skin, epithelial tissue, skeletal muscles, bones and joints, internal organs, and the cardiovascular system.
[0010] The currently approved treatment for Fabry disease is enzyme replacement therapy ("ERT"). Two α-Gal A preparations are currently available for the treatment of Fabry disease: agalsidase alfa (Replagal®, Shire Human Genetic Therapies) and agalsidase beta (Fabrazyme®, Sanofi Genzyme Corporation). These two forms of ERT are intended to offset the patient's inappropriate α-Gal A activity with a recombinant form of the enzyme administered intravenously. Although ERT is effective in many situations, there are limitations to the treatment. For example, these two α-Gal A preparations have not demonstrated a sufficient reduction in the risk of stroke, the heart muscle responds slowly to treatment, and GL-3 excretion from some kidney cell types is limited.
[0011] Another approach to treat Fabry disease has been treatment with so-called pharmacological chaperones (PCs). Such PCs include small molecule inhibitors of α-Gal A that can bind to α-Gal A and increase the stability of both the mutant and the corresponding wild-type enzymes. However, candidates for successful PC therapy should have mutations that result in the production of an enzyme that has the potential to be stabilized and folded into a conformation that allows trafficking out of the ER. Mutations that severely truncate the enzyme, such as nonsense mutations or catalytic domain mutations that prevent chaperone binding, will likely not be "rescuable" or "improvable" with PC therapy, i.e. will not respond to PC therapy.
[0012] Migalastat, also known as 1-deoxygalactonojirimycin, acts as a pharmacological chaperone for mutant α-Gal A by selectively binding to the enzyme and enhancing its stability as well as aiding in the folding of the enzyme into its correct three-dimensional shape. This stabilization of α-Gal A allows the cell's quality control mechanisms to recognize the proper folding of the enzyme, increasing its trafficking to lysosomes so it can perform its intended biological function of metabolizing GL-3. As a result of restoring proper trafficking of α-Gal A from the ER to lysosomes, migalastat hydrochloride also reduces the accumulation of misfolded proteins in the ER, thus reducing stress on the cell and some inflammatory-like responses that may be contributing factors in Fabry disease. It is estimated that approximately 35-50% of Fabry patients worldwide have a mutation that is amenable to treatment with migalastat.
[0013] Migalastat and its salt, migalastat hydrochloride, have been subjected to multiple in vitro and in vivo preclinical and even clinical trials. Migalastat has been shown to increase the amount of intracellular α-Gal A protein and enhance the transport of the mutant enzyme to lysosomes. It has also been generally well tolerated. However, developmental toxicity was observed when high doses were tested in pregnant rabbits. Despite the fact that these doses also have maternal toxicity, migalastat is currently not recommended for use during pregnancy. Summary of the Invention [Problem to be solved by the invention]
[0014] Thus, there remains a need for therapies for the treatment of Fabry disease in pregnant patients. [Means for solving the problem]
[0015] One aspect of the invention relates to a method of treating Fabry disease in a pregnant patient in need thereof. In various embodiments of this aspect, the method comprises administering to the patient once every other day a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg free base equivalent (FBE) of migalastat or a salt thereof.
[0016] In one or more embodiments, the patient becomes pregnant after the start of treatment. In some embodiments, the patient was not instructed to practice effective birth control at the time of treatment before starting treatment. In some embodiments, the patient does not practice effective birth control at the time of treatment.
[0017] In one or more embodiments, the patient is pregnant prior to initiating treatment. In some embodiments, the patient is known to be pregnant prior to initiating treatment. In some embodiments, the patient is not known to be pregnant prior to initiating treatment.
[0018] In some embodiments, treatment is discontinued upon identification of the patient's pregnancy.
[0019] In one or more embodiments, the patient's pregnancy results in the birth of a child having a gestational age of at least 37 weeks. In some embodiments, the patient's pregnancy results in the birth of a child of normal weight based on the child's gestational age. In some embodiments, the patient's pregnancy results in a child without birth defects.
[0020] In one or more embodiments, the therapeutically effective dose is about 123 mg FBE of migalastat or a salt thereof. In some embodiments, the therapeutically effective dose is about 123 mg of migalastat free base. In some embodiments, the therapeutically effective dose is about 150 mg of migalastat hydrochloride.
[0021] In one or more embodiments, the salt of migalastat is migalastat hydrochloride.
[0022] In one or more embodiments, the formulation is administered for at least 2 weeks. In some embodiments, the formulation is administered for at least 6 weeks. In some embodiments, the formulation is administered for at least 12 weeks.
[0023] In one or more embodiments, the formulation is administered for at least 2 weeks during the patient's pregnancy. In some embodiments, the formulation is administered for at least 6 weeks during the patient's pregnancy. In some embodiments, the formulation is administered for at least 12 weeks during the patient's pregnancy.
[0024] In one or more embodiments, the formulation is administered during the first trimester of the patient's pregnancy. In some embodiments, the formulation is administered during the second trimester of the patient's pregnancy. In some embodiments, the formulation is administered during the first 16 weeks of the patient's pregnancy.
[0025] In one or more embodiments, the formulation comprises a solid formulation. In some embodiments, the formulation comprises an oral dosage form. In some embodiments, the oral dosage form comprises a tablet, capsule, or solution.
[0026] Another aspect of the invention relates to a method of treating Fabry disease in a female patient of childbearing potential, hi various embodiments of this aspect, the method comprises administering to the patient once every other day a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg FBE of migalastat or a salt thereof, wherein the patient is not instructed to practice effective birth control at the time of treatment prior to initiation of treatment.
[0027] In one or more embodiments, the patient becomes pregnant after initiation of treatment. In some embodiments, the patient is not on effective birth control at the time of treatment.
[0028] In some embodiments, treatment is discontinued upon identification of the patient's pregnancy.
[0029] In one or more embodiments, the patient's pregnancy results in the birth of a child having a gestational age of at least 37 weeks. In some embodiments, the patient's pregnancy results in the birth of a child of normal weight based on the child's gestational age. In some embodiments, the patient's pregnancy results in a child without birth defects.
[0030] In one or more embodiments, the therapeutically effective dose is about 123 mg FBE of migalastat or a salt thereof. In some embodiments, the therapeutically effective dose is about 123 mg of migalastat free base. In some embodiments, the therapeutically effective dose is about 150 mg of migalastat hydrochloride.
[0031] In one or more embodiments, the salt of migalastat is migalastat hydrochloride.
[0032] In one or more embodiments, the formulation is administered for at least 2 weeks. In some embodiments, the formulation is administered for at least 6 weeks. In some embodiments, the formulation is administered for at least 12 weeks.
[0033] In one or more embodiments, the formulation is administered for at least 2 weeks during the patient's pregnancy. In some embodiments, the formulation is administered for at least 6 weeks during the patient's pregnancy. In some embodiments, the formulation is administered for at least 12 weeks during the patient's pregnancy.
[0034] In one or more embodiments, the formulation is administered during the first trimester of the patient's pregnancy. In some embodiments, the formulation is administered during the second trimester of the patient's pregnancy. In some embodiments, the formulation is administered during the first 16 weeks of the patient's pregnancy.
[0035] In one or more embodiments, the formulation comprises a solid formulation. In some embodiments, the formulation comprises an oral dosage form. In some embodiments, the oral dosage form comprises a tablet, capsule, or solution.
[0036] Various embodiments are listed below. It will be understood that the embodiments listed below can be combined not only as listed below, but also in other suitable combinations within the scope of the present invention. [Brief description of the drawings]
[0037] [Figure 1A-E] The complete DNA sequence of the human wild-type GLA gene (SEQ ID NO:1) is shown. [Diagram 2] The wild-type α-Gal A protein (SEQ ID NO:2) is shown. [Diagram 3] The nucleic acid sequence encoding the wild-type α-Gal A protein (SEQ ID NO:3) is shown. [Figure 4] Shown is a fetal magnetic resonance imaging (MRI) image in the coronal plane during the patient's pregnancy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] Before describing certain example embodiments of the invention, it is to be understood that the invention is not limited to the details of construction or method steps set forth in the following description, as the invention is capable of other embodiments and of being practiced or carried out in various ways.
[0039] Various aspects of the present invention relate to methods of treating Fabry disease in pregnant patients. Another aspect of the present invention relates to methods of treating Fabry disease in female patients of childbearing potential. Surprisingly, it has been found that patients treated with migalastat for the first 16 weeks of pregnancy give birth to "normal" offspring without defects or other abnormalities. By extension, it is believed that Fabry disease can be successfully treated with migalastat in pregnant patients without adverse effects on the patient or the developing offspring.
[0040] definition The terms used herein generally have their ordinary meaning in the art, within the context of this invention and in the specific context in which each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide further guidance to the practitioner in describing the formulations and methods of the invention and how to make, use and practice the same.
[0041] The term "Fabry disease" refers to an X-linked inborn error of glycosphingolipid catabolism resulting from deficient activity of lysosomal α-galactosidase A. This defect leads to the accumulation of globotriaosylceramide ("GL-3", also known as Gb3 or ceramide trihexoside) and related glycosphingolipids in vascular endothelial lysosomes in the heart, kidney, skin, and other tissues.
[0042] A "carrier" is a female in which one X chromosome contains a defective α-Gal A gene and one X chromosome contains a normal gene, and there is X chromosome inactivation of the normal allele in one or more cell types. Carriers are often diagnosed with Fabry disease.
[0043] "Patient" or "subject" refers to a female human.
[0044] "Fabry patient" refers to an individual with mutant α-Gal A, as further defined below, who has been diagnosed with or is suspected of having Fabry disease. Trait markers for Fabry disease may appear with equal prevalence in hemizygous male and female carriers, although females are typically affected with less severe disease.
[0045] Human α-galactosidase A (α-Gal A) refers to the enzyme encoded by the human GLA gene. The complete DNA sequence of α-Gal A, including introns and exons, is available under GenBank Accession No. X14448.1 and is shown in SEQ ID NO:1 and Figures 1A-E. The human α-Gal A enzyme consists of 429 amino acids and is available under GenBank Accession Nos. X14448.1 and U78027.1 and is shown in SEQ ID NO:2 and Figure 2. The nucleic acid sequence including only the coding region (i.e., exons) of SEQ ID NO:1 is shown in Figure 3 (SEQ ID NO:3).
[0046] The term "mutant protein" includes proteins that have a mutation in the gene encoding the protein that prevents the protein from achieving a stable conformation under conditions normally present in the ER. Failure to achieve a stable conformation results in significant amounts of the enzyme not being transported to the lysosome but rather being degraded. Such mutations are sometimes referred to as "conformational mutants." Such mutations include, but are not limited to, missense mutations, and small in-frame deletions and insertions.
[0047] As used herein in one embodiment, the term "mutant α-Gal A" includes α-Gal A that has a mutation in the gene encoding α-Gal A that prevents the enzyme from achieving a stable conformation under conditions normally present in the ER. The inability to achieve a stable conformation results in a significant amount of the enzyme not being transported to lysosomes but rather being degraded.
[0048] As used herein, the term "pharmacological chaperone" ("PC") refers to any molecule, including small molecules, proteins, peptides, nucleic acids, carbohydrates, etc., that specifically binds to a protein and has one or more of the following effects: (i) promotes the formation of a stable molecular conformation of the protein; (ii) induces trafficking of the protein from the ER to another cellular site, preferably the native cellular site, i.e., prevents ER-associated degradation of the protein; (iii) prevents aggregation of misfolded proteins; and / or (iv) restores or enhances at least some wild-type function and / or activity to a protein. For example, a compound that specifically binds to α-Gal A means that it binds to and exerts a chaperone effect on that enzyme and not on a general group of related or unrelated enzymes. More specifically, the term does not refer to endogenous chaperones, such as BiP, or non-specific agents, i.e., chemical chaperones, that have demonstrated non-specific chaperone activity on a variety of proteins, such as glycerol, DMSO, or heavy water. In the present invention, the SPC may be a reversible competitive inhibitor.
[0049] A "competitive inhibitor" of an enzyme may refer to a compound that is structurally similar to the chemical and molecular structure of the enzyme substrate and binds to the enzyme at approximately the same location as the substrate. Thus, the inhibitor competes for the same active site as the substrate molecule, thus increasing the Km. Competitive inhibition is usually reversible, i.e., a competitive inhibitor can bind reversibly, provided that sufficient substrate molecules are available to displace the inhibitor. Thus, the amount of enzyme inhibition depends on the inhibitor concentration, the substrate concentration, and the relative affinities of the inhibitor and substrate for the active site.
[0050] As used herein, the term "specifically binds" refers to the interaction of a pharmacological chaperone with a protein, such as α-Gal A, specifically with amino acid residues in the protein that are directly involved in contact with the pharmacological chaperone. A pharmacological chaperone specifically binds to a target protein, such as α-Gal A, to exert a chaperone effect on that protein and not on a general group of related or unrelated proteins. The amino acid residues in a protein that interact with a given pharmacological chaperone may or may not be within the "active site" of the protein. Specific binding can be assessed by routine binding assays or by structural studies, such as co-crystallization, NMR, etc. The active site of α-Gal A is the substrate binding site.
[0051] "Deficient α-Gal A activity" refers to α-Gal A activity in cells from a patient that is below the normal range when compared (using the same methods) to the activity in normal individuals who do not have or are not suspected of having Fabry disease or any other disease (particularly hematological disorders).
[0052] As used herein, the terms "enhancing a-Gal A activity" or "increasing a-Gal A activity" refer to increasing the amount of a-Gal A in a stable conformation in a cell contacted with an a-Gal A specific pharmacological chaperone compared to the amount in a cell (preferably of the same cell type, or the same cell, e.g., at an earlier stage) that has not been contacted with the a-Gal A specific pharmacological chaperone. The terms also refer to increasing the trafficking of a-Gal A to lysosomes in a cell contacted with an a-Gal A specific pharmacological chaperone compared to the trafficking of a-Gal A not contacted with the pharmacological chaperone specific for that protein. These terms refer to both wild type and mutant a-Gal A. In one embodiment, the increase in the amount of a-Gal A in a cell is measured by measuring the hydrolysis of an artificial substrate in lysates from cells treated with SPC. Increased hydrolysis is indicative of increased a-Gal A activity.
[0053] The term "α-Gal A activity" refers to the normal physiological function of wild-type α-Gal A in a cell. For example, α-Gal A activity includes the hydrolysis of GL-3.
[0054] A "responder" is an individual diagnosed with or suspected of having a lysosomal storage disorder, e.g., Fabry disease, whose cells respond to contact with SPC by displaying a sufficient increase in a-Gal A activity and / or a reduction in symptoms or an improvement in a surrogate marker, respectively. Non-limiting examples of improvement in a surrogate marker of Fabry are lyso-Gb3 and those disclosed in U.S. Patent Application Publication No. 2010 / 0113517.
[0055] Non-limiting examples of improvements in surrogate markers of Fabry disease disclosed in U.S. Patent Application Publication No. 2010 / 0113517 include increased α-Gal A levels or activity in cells (e.g., fibroblasts) and tissues; reduced GL-3 accumulation; reduced plasma concentrations of homocysteine and vascular cell adhesion molecule-1 (VCAM-1); reduced GL-3 accumulation in cardiomyocytes and valvular fibrocytes; reduced cardiac hypertrophy (especially the left ventricle), reduced valvular regurgitation, and arrhythmias; reduced proteinuria; reduced urinary concentrations of lipids such as CTH, lactosylceramide, ceramide, and increased urinary concentrations of glucosylceramide and sphingomyelin; absence of lamellar inclusions (zebra bodies) in glomerular epithelial cells; improved renal function; reduced hypohidrosis; absence of angiokeratoma; and improvement in hearing abnormalities such as high frequency sensorineural hearing loss, progressive hearing loss, sudden hearing loss, or tinnitus. Improvement of neurological symptoms includes prevention of transient ischemic attacks (TIA) or stroke; and reduction of neuropathic pain manifested as acroparesthesia (burning or tingling pain in the extremities). Another clinical marker that may determine Fabry disease is the prevalence of adverse cardiovascular symptoms. Common cardiac-related signs and symptoms of Fabry disease include left ventricular hypertrophy, valvular disease (particularly mitral valve prolapse and / or regurgitation), premature coronary artery disease, angina, myocardial infarction, conduction abnormalities, arrhythmias, and congestive heart failure.
[0056] A dose that achieves one or more of the above mentioned responses is a "therapeutically effective dose."
[0057] The phrase "pharmaceutical acceptable" refers to molecular entities and compositions that are physiologically tolerable and typically do not produce adverse reactions when administered to humans. In some embodiments, as used herein, the term "pharmaceutical acceptable" means approved by a federal or state regulatory agency for use in animals, more particularly humans, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias. With respect to pharmaceutical carriers, the term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers may be sterile liquids, such as water and oils. As carriers, water or aqueous solutions, saline solutions, and aqueous dextrose and glycerol solutions are preferably employed, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin, 18th Edition, or other editions.
[0058] The terms "about" and "approximately" are generally intended to mean an acceptable degree of error of the measured quantity, given the nature or precision of the measurement. Typical exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, particularly in biological systems, the terms "about" and "approximately" can mean values within an order of magnitude, preferably within 10-fold or 5-fold, and more preferably within 2-fold, of a given value. Numerical quantities provided herein are approximate unless otherwise stated, i.e., the terms "about" or "approximately" can be implied even when not explicitly stated.
[0059] The term "enzyme replacement therapy" or "ERT" refers to the introduction of a purified, non-native enzyme to an individual having a deficiency in such enzyme. The administered protein can be obtained from a natural source or by recombinant expression (as described in more detail below). The term also refers to the introduction of a purified enzyme to an individual who otherwise requires or would benefit from administration of the purified enzyme (e.g., an individual suffering from an enzyme deficiency). The introduced enzyme can be a purified recombinant enzyme produced in vitro or a protein purified from an isolated tissue or fluid, such as from the placenta or animal milk or from a plant.
[0060] The term "pregnancy" refers to a female patient having a baby or other young developing within her body. The period during which the patient is pregnant may be referred to as the patient's pregnancy. As discussed below, the onset of the patient's pregnancy will not coincide with the foetal age of the baby. Thus, the duration of the patient's pregnancy and the foetal age of the resulting baby will vary.
[0061] The term "pregnant" refers to the conception of a child or other young. In humans, this is the point at which an oocyte (egg cell) and sperm combine to form an embryo. As described herein, a patient may or may not be aware that they are pregnant.
[0062] The term "patient of childbearing potential" refers to a female patient who is pregnant or capable of becoming pregnant. Patients who are utilizing effective birth control but are otherwise capable of becoming pregnant are still referred to as patients of childbearing potential.
[0063] The term "known to be pregnant" refers to a patient who has tested positive for pregnancy. Suitable pregnancy tests include, but are not limited to, a urine test, a blood test, or an ultrasound test.
[0064] The term "effective birth control" refers to a contraceptive method that relies on a physical or physiological barrier to prevent a patient from becoming pregnant ("birth control") and that is effective about 90% or more of the time when used as directed. Suitable effective birth control methods include, but are not limited to, hormonal contraceptives (pills, shots, patches, etc.), surgical methods (vasectomy or tubal ligation), intrauterine devices (IUDs), and physical barriers (condoms, diaphragms, cervical caps, etc.).
[0065] The term "fetal age" refers to the common measure of age of a pregnant offspring or young body before birth. Fetal age is typically measured from the end of the patient's last menstrual cycle. Thus, at the start of pregnancy, a child can already be considered to have a fetal age of about 2 weeks.
[0066] The term "trimester" refers to the period of pregnancy. Pregnancy is typically divided into three trimesters of approximately equal duration. In humans, the average gestational age is 280 days or 40 weeks. The term "first trimester" refers to the period from the onset of pregnancy to about 13 weeks of gestational age. The term "second trimester" refers to the period from about 14 weeks of gestational age to about 27 weeks of gestational age. The "third trimester" refers to the period from about 28 weeks of gestational age to the birth of the offspring.
[0067] The term "normal weight" refers to a birth weight between the 10th and 90th percentile of birth weight based on the child's sex and gestational age at birth. Birth weight percentile charts are commonly known in the art as Fenton growth charts. As an example, a baby boy born at 33 weeks gestational age with a birth weight of 2000 g would be considered to have a normal weight (50th percentile) despite the fact that the WHO standard would consider the baby to have a low birth weight.
[0068] The term "birth defects" refers to physical or biochemical abnormalities resulting from the use of migalastat. In other words, "birth defects" should be understood to refer to teratogenic birth defects as a result of taking migalastat. "Birth defects" should not be understood to refer to abnormalities resulting from other environmental influences during pregnancy or any genetic abnormalities that may be inherited (e.g., α-gal A mutations).
[0069] As used herein, the term "free base equivalent" or "FBE" refers to the amount of migalastat present in migalastat or its salt. In other words, the term "FBE" refers to either the amount of migalastat free base or the equivalent amount of migalastat free base provided by a salt of migalastat. For example, based on the weight of the hydrochloride, 150 mg of migalastat hydrochloride only provides the same amount of migalastat as 123 mg of migalastat in free base form. Other salts are expected to have different conversion factors depending on the molecular weight of the salt.
[0070] The term "migalastat," unless expressly specified otherwise, includes migalastat free base or a pharma- ceutically acceptable salt thereof (eg, migalastat HCl).
[0071] Pharmacological Chaperones Binding of small molecule inhibitors of LSD-related enzymes can increase the stability of both mutant and corresponding wild-type enzymes (see U.S. Patent Nos. 6,274,597; 6,583,158; 6,589,964; 6,599,919; 6,916,829, and 7,141,582, all of which are incorporated herein by reference). In particular, administration of small molecule derivatives of glucose and galactose, which are specific and selective competitive inhibitors of some target lysosomal enzymes, effectively increases the stability of the enzymes in cells in vitro, thereby increasing the trafficking of the enzymes to lysosomes. Thus, increasing the amount of enzymes in lysosomes is expected to increase the hydrolysis of enzyme substrates. The original theory behind this strategy was as follows: Because mutant enzyme proteins are unstable in the ER (Ishii et al., Biochem. Biophys. Res. Comm. 1996;220:812-815), they are delayed in the normal trafficking pathway (ER → Golgi → endosomes → lysosomes) and are prematurely degraded. Thus, compounds that bind to and increase the stability of mutant enzymes can act as "chaperones" for the enzymes, increasing the amount that can leave the ER and be transported to lysosomes. In addition, because folding and trafficking of some wild-type proteins is incomplete, and in some cases up to 70% of some wild-type proteins are degraded before reaching their final cellular site, chaperones can be used to stabilize wild-type enzymes, increasing the amount of enzyme that can leave the ER and be transported to lysosomes. This strategy has been shown to increase the activity of several lysosomal enzymes in vitro and in vivo, including β-glucocerebrosidase and α-glucosidase, deficiencies of which are associated with Gaucher and Pompe diseases, respectively.
[0072] In one or more embodiments, the pharmacological chaperone comprises migalastat or a salt thereof. The compound migalastat, also known as 1-deoxygalactonojirimycin (1-DGJ) or (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol, is a compound having the following chemical formula: TIFF2024161361000002.tif54170
[0073] As discussed herein, pharmaceutically acceptable salts of migalastat may also be used in the present invention.When using a salt of migalastat, the dosage of the salt will be adjusted so that the dose of migalastat taken by the patient is equivalent to the amount that would have been taken if migalastat free base was used.One example of a pharmaceutically acceptable salt of migalastat is migalastat HCl. TIFF2024161361000003.tif48170
[0074] Migalastat is a low molecular weight iminosugar and an analogue of the terminal galactose of GL-3. In vitro and in vivo pharmacological studies have demonstrated that migalastat acts as a pharmacological chaperone, binding selectively and reversibly with high affinity to the active site of wild-type α-Gal A and specific mutant forms of α-Gal A (the genotypes are referred to as HEK assay-compatible mutations). Binding of migalastat stabilizes these mutant forms of α-Gal A in the endoplasmic reticulum and promotes their proper trafficking to lysosomes, where dissociation of migalastat allows α-Gal A to reduce GL-3 and other substrate levels. Approximately 30-50% of patients with Fabry disease have HEK assay-compatible mutations; the majority of these are associated with the classical phenotype of the disease.
[0075] HEK assay applicable mutations include at least those mutations listed in a pharmacological reference table (e.g., those listed in the U.S. or international product label for a migalastat product such as GALAFOLD®). As used herein, a "pharmacological reference table" refers to any publicly accessible written or electronic record contained in either the product label within the packaging of a migalastat product (e.g., GALAFOLD®) or a website accessible by a healthcare provider, which communicates whether a particular mutation or variant will respond to migalastat (e.g., GALAFOLD®) PC therapy, and is not necessarily limited to written records presented in tabular form. Thus, in one embodiment of the present invention, a "pharmacological reference table" refers to any depository of information that includes one or more applicable mutations or variants. Exemplary pharmacological reference tables for HEK assay applicable mutations can be found in the Summary of Product Characteristics and / or Prescribing Information for GALAFOLD® in the various countries where GALAFOLD® is approved for use, or on websites such as www.galafoldamenabilitytable.com and www.fabrygenevariantsearch.com, each of which is hereby incorporated by reference in its entirety.
[0076] An exemplary pharmacological reference list for HEK assay amenable mutations is provided below in Table 1. In one or more embodiments, when double mutations are present on the same chromosome (male and female), the patient is considered amenable to the HEK assay if the double mutation is present in one entry of Table 1 (e.g., D55V / Q57L). In some embodiments, when double mutations are present on different chromosomes (females only), the patient is considered amenable to the HEK assay if either one of the individual mutations is present in Table 1.
[0077] TIFF2024161361000004.tif65170
[0078] TIFF2024161361000005.tif218170
[0079] TIFF2024161361000006.tif221170
[0080] TIFF2024161361000007.tif218170
[0081] TIFF2024161361000008.tif218170
[0082] TIFF2024161361000009.tif221170
[0083] TIFF2024161361000010.tif219170
[0084] TIFF2024161361000011.tif218170
[0085] TIFF2024161361000012.tif219170
[0086] TIFF2024161361000013.tif130170
[0087] Any PC against α-Gal A may be used in combination with any of the other embodiments of the invention, such as methods of treating patients with Fabry disease, methods of enhancing α-galactosidase A in patients diagnosed with or suspected of having Fabry disease, embodiments relating to the use of a pharmacological chaperone against α-galactosidase A for the manufacture of a medicament for treating patients diagnosed with Fabry disease, or embodiments relating to a pharmacological chaperone against α-galactosidase A for use in treating patients diagnosed with Fabry disease, as well as embodiments relating to a suitable dose of PC and the treatment of pregnant Fabry patients of childbearing potential.
[0088] Formulation and Administration Thus, in one or more embodiments, a Fabry patient is administered migalastat or a salt thereof once every other day (also referred to as "QOD"). In various embodiments, the doses described herein relate to migalastat hydrochloride or an equivalent dose of migalastat or a salt thereof other than the hydrochloride salt. In some embodiments, these doses relate to the free base of migalastat. In alternative embodiments, these doses relate to a salt of migalastat. In further embodiments, the salt of migalastat is migalastat hydrochloride.
[0089] The administration of migalastat or a salt of migalastat is referred to herein as "migalastat therapy."
[0090] An effective amount of migalastat or a salt thereof can range from about 100 mg FBE to about 150 mg FBE. Exemplary doses include about 100 mg FBE, about 105 mg FBE, about 110 mg FBE, about 115 mg FBE, about 120 mg FBE, about 123 mg FBE, about 125 mg FBE, about 130 mg FBE, about 135 mg FBE, about 140 mg FBE, about 145 mg FBE, or about 150 mg FBE.
[0091] It is also noted here that 150 mg of migalastat hydrochloride is equivalent to 123 mg of the free base form of migalastat. Thus, in one or more embodiments, the dose is 150 mg of migalastat hydrochloride administered once every other day, or an equivalent dose of migalastat or its salts other than hydrochloride. As indicated above, this dose is referred to as 123 mg FBE of migalastat. In a further embodiment, the dose is 150 mg of migalastat hydrochloride administered every other day. In another embodiment, the dose is 123 mg of migalastat free base administered every other day.
[0092] In various embodiments, the effective amount is about 122 mg, about 128 mg, about 134 mg, about 140 mg, about 146 mg, about 150 mg, about 152 mg, about 159 mg, about 165 mg, about 171 mg, about 177 mg, or about 183 mg of migalastat hydrochloride.
[0093] Thus, in various embodiments, migalastat therapy includes administration of 150 mg migalastat hydrochloride every other day, such as 123 mg FBE once every other day.
[0094] The administration of migalastat or a salt thereof may be for a certain period of time. In one or more embodiments, migalastat or a salt thereof is administered for at least 2 weeks, for example, at least 6, 12, or 16 weeks, or at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks. In one or more embodiments, migalastat is administered for at least 28 days, for example, at least 30, 60, or 90 days, or at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 30, or 36 months, or at least 1, 2, 3, 4, or 5 years. In various embodiments, the migalastat therapy is chronic migalastat therapy for at least 6 months, for example, at least 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 30, or 36 months, or at least 1, 2, 3, 4, or 5 years.
[0095] The administration of migalastat or a salt thereof according to the present invention may be in a formulation suitable for any route of administration, but is preferably administered in an oral dosage form such as a tablet, capsule, or solution. As an example, a patient is orally administered capsules each containing 150 mg of migalastat hydrochloride or an equivalent dose of migalastat or a salt thereof other than the hydrochloride salt.
[0096] In some embodiments, the PC (e.g., migalastat or a salt thereof) is administered orally. In one or more embodiments, the PC (e.g., migalastat or a salt thereof) is administered by injection. The PC may be accompanied by a pharma- ceutically acceptable carrier, which may depend on the method of administration.
[0097] In one embodiment of the invention, the PC (e.g., migastat or a salt thereof) is administered as a monotherapy and may be in a form suitable for any route of administration, for example orally in tablet or capsule or liquid form, in a sterile aqueous solution for injection, or provided as a lyophilized powder that is added to the replacement enzyme formulation during or immediately after reconstitution to prevent enzyme aggregation in vitro prior to administration.
[0098] When the chaperone compound is formulated for oral administration, tablets or capsules may be prepared by conventional means with pharma- ceutically acceptable excipients such as binders (e.g., pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form, for example, of solutions, syrups, or suspensions, or may be prepared as a dry preparation for constitution with water or another suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharma- ceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl p-hydroxybenzoate or sorbic acid). The formulations may also contain buffer salts, flavoring, coloring, and sweetening agents as appropriate. Formulations for oral administration may be suitably formulated to give controlled release of the active chaperone compound.
[0099] Pharmaceutical formulations of PC (e.g., migastat or its salts) suitable for parenteral / injectable use generally include sterile aqueous solutions (if water soluble), or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, benzyl alcohol, sorbic acid, and the like. In many cases, it may be advisable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents which delay absorption, for example, aluminum monostearate and gelatin.
[0100] Sterile injectable solutions are prepared by blending the required amount of purified enzyme (if present) and PC (e.g., migalastat or its salt) in an appropriate solvent with various other ingredients as listed above as needed, followed by filtration or terminal sterilization. In general, dispersions are prepared by blending the various sterilized active ingredients in a sterile vehicle containing the basic dispersion medium and other required ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution thereof.
[0101] The formulation may contain excipients. Pharmaceutically acceptable excipients that may be included in the formulation are buffers, such as citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer, amino acids, urea, alcohols, ascorbic acid, phospholipids; proteins such as serum albumin, collagen, and gelatin; salts such as EDTA or EGTA, and sodium chloride; liposomes; polyvinylpyrollidone; sugars such as dextran, mannitol, sorbitol, and glycerol; propylene glycol and polyethylene glycol (e.g., PEG-4000, PEG-6000); glycerol; glycine or other amino acids; and lipids. Buffer systems for use with the formulation include citrate; acetate; bicarbonate; and phosphate buffers. Phosphate buffers are a preferred embodiment.
[0102] The route of administration of the chaperone compound may be oral or parenteral, including intravenous, subcutaneous, intra-arterial, intraperitoneal, intraocular, intramuscular, buccal, rectal, intravaginal, intraorbital, intracerebral, intradermal, intracranial, intraspinal, intraventricular, intrathecal, intracisternal, intravesicular, intrapulmonary, intranasal, transmucosal, transdermal, or by inhalation.
[0103] Administration of the chaperone compound in the above-mentioned parenteral formulations may be by periodic injection of a bolus of the formulation, or by intravenous or intraperitoneal administration from an external (e.g., an IV bag) or internal (e.g., a bioerodible implant) reservoir.
[0104] The embodiments relating to pharmaceutical formulations and administration may be combined with any of the other embodiments of the invention, such as embodiments relating to methods of treating patients with Fabry disease, methods of enhancing a-Gal A in patients diagnosed with or suspected of having Fabry disease, the use of a pharmacological chaperone to a-Gal A for the manufacture of a medicament for treating patients diagnosed with Fabry disease, or a pharmacological chaperone to a-Gal A for use in treating patients diagnosed with Fabry disease, as well as embodiments relating to applicable mutations, PCs and suitable dosages thereof.
[0105] In one or more embodiments, the PC (e.g., migalastat or its salt) is administered in combination with ERT. ERT increases the amount of protein by exogenously introducing wild-type or biologically functional enzymes by injection. This therapy has been developed for many genetic disorders, including lysosomal storage disorders such as Fabry disease, as described above. After injection, the exogenous enzyme is assumed to be taken up by tissues via non-specific or receptor-specific mechanisms. In general, the uptake efficiency is not high and the circulation time of exogenous proteins is short. In addition, exogenous proteins are unstable and subject to rapid intracellular degradation, as well as the possibility of adverse immune reactions with subsequent treatment. In one or more embodiments, the chaperone is administered simultaneously with the replacement enzyme (e.g., replacement α-Gal A). In some embodiments, the chaperone is formulated with the replacement enzyme (e.g., replacement α-Gal A).
[0106] In one or more embodiments, the patient is switched from ERT to migalastat therapy.In some embodiments, the patient undergoing ERT is identified, the patient's ERT is discontinued, and the patient begins to undergo migalastat therapy.The migalastat therapy can be according to any of the methods described herein.
[0107] Throughout this specification, the phrases "one embodiment," "a particular embodiment," "various embodiments," "one or more embodiments," or "an embodiment" mean that a particular feature, structure, material, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, the appearance of the phrases "in one or more embodiments," "in a particular embodiment," "various embodiments," "in one embodiment," "in an embodiment," etc. in various places throughout this specification do not necessarily refer to the same embodiment of the invention. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments.
[0108] Although the invention herein has been described with reference to particular embodiments, it should be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the method and apparatus of the present invention without departing from the spirit and scope of the invention. Therefore, it is intended that the present invention cover such modifications and variations provided they come within the scope of the appended claims and their equivalents. EXAMPLES
[0109] Example 1: Patients treated with migalastat during pregnancy A Caucasian woman was diagnosed with Fabry disease based on renal biopsy and mutation analysis (GLA p.R112H) in October 2005. Treatment of the patient's Fabry disease began with agalsidase alfa (ERT) in 2009. After initiation of treatment, the patient showed no progression of renal, cardiac, or neurological symptoms.
[0110] In April 2012, the patient had a proteinuria level of 187 mg / 24 h. In May 2012, the patient had a proteinuria level of 83 mg / 24 h. In late May 2012, the patient, now 35 years old, began participating as part of a Phase 3 clinical trial of migalastat. The patient was also taking hormonal contraception.
[0111] The study was a phase 3 trial of migalastat therapy in ERT-experienced Fabry patients. Eligible patients were 16-74 years of age, had genetically confirmed Fabry disease, had been receiving ERT for ≥12 months, had a GLA mutation resulting in a mutant protein likely to respond to migalastat based on the human embryonic kidney 293 (HEK) assay used at enrollment, and had an estimated glomerular filtration rate (eGFR) ≥30 ml / min / 1.73 m 2 and had a stable ERT dose level and regimen for at least 3 months.
[0112] Eligibility - Following baseline assessment, patients were randomized to the study group. The study group received 18 months of migalastat therapy (the control group continued ERT), followed by an additional 12 months of migalastat therapy. The migalastat dosing regimen was 150 mg migalastat hydrochloride every other day. The primary objective was to assess iohexol clearance (mGFR) after 18 months of treatment. イオヘキソール The objective of this study was to compare the effects of migalastat versus ERT on renal function as assessed by GFR measured using a 24-hour urinary protein (EGF) test. Secondary objectives were to compare the effects of migalastat versus ERT on renal function (assessed by eGFR and 24-hour urinary protein), a composite clinical outcome (assessed by time to occurrence of renal, cardiac, cerebrovascular event or death), cardiac function (assessed by echocardiography), and patient-reported outcomes (pain and quality of life).
[0113] In February 2014 (21 months into the study), the patient had a proteinuria level of 78 mg / 24 h. In May 2014, she had a proteinuria level of 2166 mg / 24 h (131 / 68 mmHg) without hypertensive symptoms. At that time, a urine test showed a negative pregnancy result.
[0114] In June 2014, persistent proteinuria (>1000 mg / 24 h) prompted a kidney biopsy and blood tests. An ultrasound confirmed pregnancy and estimated a gestational age of approximately 18 weeks. In other words, the patient was estimated to be approximately 16 weeks pregnant. She became pregnant despite taking hormonal contraception. At that time, serum analysis showed a positive pregnancy result. Both migalastat and hormonal contraception treatment were stopped at that time.
[0115] A fetal MRI was performed in September 2014. The results, provided in Figure 4, show normal fetal development based on gestational age.
[0116] In October 2014, the baby was delivered by Caesarean section. The baby was a girl, measuring 45 cm and weighing 2.29 kg without any reported birth defects. The baby had a wild-type GLA gene. The pregnancy was uneventful. In September 2015, the patient resumed ERT with agalsidase alfa via home infusion.
[0117] Summary and Conclusion As shown in the above examples, patients who took migalastat for at least the first 16 weeks of pregnancy had uneventful pregnancies and delivered babies of normal weight for gestational age, indicating that patients treated with migalastat can become pregnant and deliver normal babies upon treatment.
[0118] The patents and scientific literature referred to herein establish knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, articles and scientific literature cited herein are hereby incorporated by reference.
[0119] Although the present invention has been particularly shown and described with reference to preferred embodiments thereof, workers skilled in the art will understand that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the appended claims.
Claims
1. 1. A method of treating Fabry disease in a pregnant patient in need thereof, comprising administering to said patient once every other day a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg free base equivalent (FBE) of migalastat or a salt thereof.
2. The method of claim 1 , wherein the patient becomes pregnant after initiation of the treatment.
3. 3. The method of claim 2, wherein said patient was not instructed prior to the start of said treatment to practice effective birth control during said treatment.
4. The method of claim 2 or 3, wherein the patient was not using effective birth control at the time of treatment.
5. The method of claim 1 , wherein the patient is pregnant prior to the initiation of the treatment.
6. 6. The method of claim 5, wherein the patient is not known to be pregnant prior to the initiation of the treatment.
7. The method of any one of claims 1 to 6, wherein said treatment is discontinued upon identification of pregnancy in said patient.
8. 6. The method of claim 5, wherein the patient is known to be pregnant prior to the initiation of the treatment.
9. 9. The method of any one of claims 1 to 8, wherein the patient's pregnancy results in the birth of a child having a gestational age of at least 37 weeks.
10. 10. The method of any one of claims 1 to 9, wherein said patient's pregnancy results in the birth of a baby that is normal weight based on the gestational age of said baby.
11. 11. The method of any one of claims 1 to 10, wherein said patient's pregnancy results in a child without birth defects.
12. 12. The method of any one of claims 1 to 11, wherein the therapeutically effective dose is about 123 mg free base equivalent (FBE) of migalastat or a salt thereof.
13. The method of any one of claims 1 to 12, wherein the therapeutically effective dose is about 123 mg of migalastat free base.
14. The method according to any one of claims 1 to 12, wherein the salt of migalastat is migalastat hydrochloride.
15. 15. The method of claim 14, wherein the therapeutically effective dose is about 150 mg of migalastat hydrochloride.
16. The method of any one of claims 1 to 15, wherein the formulation is administered for at least two weeks during the patient's pregnancy.
17. The method of any one of claims 1 to 16, wherein the formulation is administered for at least 6 weeks during the pregnancy.
18. 18. The method of any one of claims 1 to 17, wherein the formulation is administered for at least 12 weeks during the patient's pregnancy.
19. The method of any one of claims 1 to 18, wherein the formulation is administered during the first trimester of the patient's pregnancy.
20. The method of any one of claims 1 to 19, wherein the formulation is administered during the second trimester of the patient's pregnancy.
21. The method of any one of claims 1 to 20, wherein the formulation is administered during the first 16 weeks of the patient's pregnancy.
22. The method of any one of claims 1 to 21, wherein the formulation comprises a solid formulation.
23. The method of any one of claims 1 to 22, wherein the formulation comprises an oral dosage form.
24. 24. The method of claim 23, wherein the oral dosage form comprises a tablet, capsule, or solution.
25. The method of any one of claims 1 to 24, wherein the patient has a HEK assay-amenable mutation in α-galactosidase A.
26. 26. The method of claim 25, wherein the mutation is disclosed in a pharmacological reference table.
27. 27. The method of claim 26, wherein the pharmacological reference table is provided in the product labeling of a migalastat product approved for the treatment of Fabry disease.
28. 28. The method of claim 27, wherein the pharmacological reference table is provided in the product label of GALAFOLD®.
29. 28. The method of claim 27, wherein the pharmacological reference table is provided on a website.
30. 30. The method of claim 29, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.
31. A method for treating Fabry disease in a female patient of childbearing potential, comprising administering to said patient once every other day a formulation comprising a therapeutically effective dose of about 100 mg to about 150 mg free base equivalent (FBE) of migalastat or a salt thereof, wherein said patient is not instructed prior to initiation of said treatment to practice effective birth control during said treatment.
32. 32. The method of claim 31 , wherein the patient becomes pregnant after initiation of the treatment.
33. 33. The method of claim 31 or 32, wherein the patient is not utilizing effective birth control at the time of treatment.
34. 34. The method of claim 32 or 33, wherein the treatment is discontinued upon identification of pregnancy in the patient.
35. 35. The method of any one of claims 32 to 34, wherein the patient's pregnancy results in the birth of a child having a gestational age of at least 37 weeks.
36. 36. The method of any one of claims 32 to 35, wherein said patient's pregnancy results in the birth of a child of normal weight based on the child's gestational age.
37. 37. The method of any one of claims 32-36, wherein pregnancy of said patient results in a child without birth defects.
38. 38. The method of any one of claims 31 to 37, wherein the therapeutically effective dose is about 123 mg free base equivalent (FBE) of migalastat or a salt thereof.
39. 39. The method of any one of claims 31-38, wherein the therapeutically effective dose is about 123 mg of migalastat free base.
40. 39. The method of any one of claims 31 to 38, wherein the salt of migalastat is migalastat hydrochloride.
41. 41. The method of claim 40, wherein the therapeutically effective dose is about 150 mg of migalastat hydrochloride.
42. The method of any one of claims 31 to 41, wherein the formulation is administered for at least two weeks.
43. The method of any one of claims 31 to 42, wherein the formulation is administered for at least 6 weeks.
44. The method of any one of claims 31 to 43, wherein the formulation is administered for at least 12 weeks.
45. 45. The method of any one of claims 32 to 44, wherein the formulation is administered for at least two weeks during the patient's pregnancy.
46. 46. The method of any one of claims 32 to 45, wherein the formulation is administered for at least 6 weeks during the patient's pregnancy.
47. 47. The method of any one of claims 32 to 46, wherein the formulation is administered for at least 12 weeks during the patient's pregnancy.
48. The method of any one of claims 32 to 47, wherein the formulation is administered during the first trimester of the patient's pregnancy.
49. The method of any one of claims 32 to 48, wherein the formulation is administered during the second trimester of the patient's pregnancy.
50. 50. The method of any one of claims 32-49, wherein the formulation is administered during the first 16 weeks of the patient's pregnancy.
51. The method of any one of claims 31 to 50, wherein the formulation comprises a solid formulation.
52. The method of any one of claims 31 to 51, wherein the formulation comprises an oral dosage form.
53. 53. The method of claim 52, wherein the oral dosage form comprises a tablet, capsule, or solution.
54. The method of any one of claims 31 to 53, wherein the patient has a HEK assay-amenable mutation in α-galactosidase A.
55. 55. The method of claim 54, wherein the mutation is disclosed in a pharmacological reference table.
56. 56. The method of claim 55, wherein the pharmacological reference table is provided in the product labeling of a migalastat product approved for the treatment of Fabry disease.
57. 57. The method of claim 56, wherein the pharmacological reference table is provided in the product label of GALAFOLD(R).
58. 57. The method of claim 56, wherein the pharmacological reference table is provided on a website.
59. 59. The method of claim 58, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.
